Cumulatively, more than 35 scientific abstracts on FYCOMPA were presented by both
In a retrospective study, researchers evaluated and compared use of all-cause and epilepsy-related healthcare services among patients, with an epilepsy diagnosis or non-febrile convulsions during the study period, treated with select AED combinations with and without FYCOMPA in a real-world clinical practice setting. The study followed patients 12 years who were treated with select AED treatment combinations, classified into three groups: FYCOMPA+ sodium channel blocker (SC), SC+SC and SC+ synaptic vesicle protein 2A binding (SV2). Outcomes were evaluated during a follow-up period of up to 12 months post-index treatment, and data was sourced from
The real-world data analysis showed the rate of all-cause hospitalization to be significantly lower in the FYCOMPA+SC group vs both the SC+SC group (adjusted rate ratio [RR]=0.71; p
(C) 2019 Electronic News Publishing, source